醫藥股回吐 石藥及藥明生物急跌逾6%至7%
醫藥股今天受壓,尤其是藥明生物(02269.HK)股價重失20天、250天及10天線,最低見46.8元,現報47.1元,回吐7.1%。高盛本周初發表報告引述藥明生物管理層指今年會如期推動80個新項目的目標,但今年利潤率或會觸底,料明年將可改善,該行指藥明生物本季交付若慢於預期,會影響2023財年利潤率
藥明康德(02359.HK)及藥明巨諾(02126.HK)股價各跌3.5%及6%,分別報92.85元及2.49元,均股價跌破10天線。百濟神州(06160.HK)失守10天線,最低見113.6元,現報115.2元,回吐6%。
其餘藍籌醫藥股也全線跌逾2%-6%,石藥(01093.HK)沽壓最大,股價失守10天線,最低見6.72元,報6.75元,回吐6.3%。
康寧傑瑞製藥-B(09966.HK)、信達生物(01801.HK)、騰盛博藥(02137.HK)、諾誠健華(09969.HK)、四環藥業(00460.HK)、開拓藥業(09939.HK)、康方生物(09926.HK)及君實(01877.HK)反覆跌逾2%-3.5%。再鼎醫藥(09688.HK)回吐6.6%報21.1元,股價失守10天線(21.9元)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.